Management of Anaemia in Prostate Cancer

REFERENCES

• Nilsson-Ehle, H.; Jagenburg, R.; Landahl, S.; Blood haemoglobin declines in the elderly: implications for reference intervals from age 70 to 88. Eur J Haematol 2000, 65, 297–305.
   PubMed Web of Science ®Google Scholar
• Guralnik, J.M.; Eisenstaedt, R.S.; Ferrucci, L.; Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 2004, 104, 2263–2268.
   PubMed Web of Science ®Google Scholar
• Makipour, S.; Kanapuru, B.; Ershler, W.B. Unexplained anemia in the elderly. Semin Hematol 2008, 45(4), 250–254.
   PubMed Web of Science ®Google Scholar
• Izaks, G.J.; Westendorp, R.G.; Knook, D.L. The definition of anemia in older persons. JAMA 1999, 281, 1714–1717.
   PubMed Web of Science ®Google Scholar
• Wu, W.C.; Schifftner, T.L.; Henderson, W.G.; Preoperative hematocrit levels and postoperative outcomes in older patients undergoing noncardiac surgery. JAMA 2007, 297, 2481–2488.
   PubMed Web of Science ®Google Scholar
• Ania, B.G.; Suman, V.J.; Fairbucks, V.F.; Incidence of anemia in older people: an epidemiologic study in a well-defined population. J Am Geriatr Soc 1997, 45, 825–831.
   PubMed Web of Science ®Google Scholar
• Artz, A.S.; Fergusson, D.; Drinka, P.J.; Prevalence of anemia in skilled-nursing home residents. Arch Gerontol Geriatr 2004, 39, 201–206.
   PubMed Web of Science ®Google Scholar
• Landi, F.; Russo, A.; Danese, P.; Anemia status, hemoglobin concentration, and mortality in nursing home older residents. J Am Med Dir Assoc 2007, 8, 322–327.
   PubMed Web of Science ®Google Scholar
• Robinson, B.; Artz, A.S.; Culleton, B.; Prevalence of anemia in the nursing home: contribution of chronic kidney disease. J Am Geriatr Soc 2007, 55, 1566–1570.
   PubMed Web of Science ®Google Scholar
• Ferlay, J.; Autier, P.; Boniol, M.; Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 18, 581–592.
   PubMed Web of Science ®Google Scholar
• Edwards, B.K.; Brown, M.L.; Wingo, P.A.; Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005, 97(19), 1407–1427.
   PubMed Web of Science ®Google Scholar
• Gabrilove, J. Overview: erythropoiesis, anemia and the impact of erythropoietin. Semin Hematol 2000, 37(4 Suppl. 6), 1–3.
   PubMed Web of Science ®Google Scholar
• Ludwig, H.; Van Belle, S.; Barrett-Lee, P.; The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004, 40, 2293–2306.
   PubMed Web of Science ®Google Scholar
• Caro, J.J.; Salas, M.; Ward, A.; Anemia as an independent prognostic factor for survival in patients with cancer. Cancer 2001, 91, 2214–2221.
   PubMed Web of Science ®Google Scholar
• Bokemeyer, C.; Aapro, M.S.; Courdi, A.; EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007, 43(2), 258–270.
   PubMed Web of Science ®Google Scholar
• Henke, M.; Laszig, R.; Rube, C.; Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003, 362, 1255–1260.
   PubMed Web of Science ®Google Scholar
• Leyland-Jones, B.; Semiglazov, V.; Pawlicki, M.; Mantaining normal haemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005, 23, 5960–5972.
   PubMed Web of Science ®Google Scholar
• Wright, J.R.; Ung, Y.C.; Julian, J.A.; Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007, 25, 1027–1032.
   PubMed Web of Science ®Google Scholar
• Smith, R.E. Jr; Aapro, M.S.; Ludwig, H.; Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008, 26, 1040–1050.
   PubMed Web of Science ®Google Scholar
• Auerbach, M.; Ballard, H.; Trout, R.; Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004, 22, 1301–1307.
   PubMed Web of Science ®Google Scholar
• Terret, C.; Albrand, G.; Droz, J.P. Geriatric assessment in elderly patients with prostate cancer. Clin Prostate Cancer 2004, 2(4), 236–240.
   PubMedGoogle Scholar
• NCCN guidelines version 2008.1 about fatigue. Available from URL: http://www.nccn.org/professionals/physiciangls/PDF/fatigue.pdf [accessed May 1, 2008].
   Google Scholar
• Khafagy, R.; Shackley, D.; Samuel, J.; Complications arising in the final year of life in men dying from advanced prostate cancer. J Palliat Med 2007, 10, 705–711.
   PubMed Web of Science ®Google Scholar
• Dunn, A.; Carter, J.; Carter, H. Anemia in the end of life: prevalence, significance, and causes in patients receiving palliative care. J Pain Symptom Manage 2003, 26(6), 1132–1139.
   PubMed Web of Science ®Google Scholar
• Nilsson-Ehle, H.; Jagenburg, R.; Landahl, S.; Serum cobalamins in the elderly: a longitudinal study of a representative population sample from age 70 to 81. Eur J Haematol 1991, 47(1), 10–16.
   PubMed Web of Science ®Google Scholar
• Toliusiene, J.; Lesauskaite, V. The nutritional status of older men with advanced prostate cancer and factors affecting it. Support Care Cancer 2004, 12(10), 716–719.
   PubMed Web of Science ®Google Scholar
• Catalina, F.; Milewich, L.; Kumar, V.; Dietary dehydroepiandrosterone inhibits bone marrow and leukemia cell transplants: role of food restriction. Exp Biol Med 2003, 228, 1303–1320.
   Web of Science ®Google Scholar
• Weinstein, S.J.; Hartman, T.J; Stolzenberg-Solomon, R.; Null association between prostate cancer and serum folate, vitamin B6, vitamin B12, and homocysteine. Cancer Epidemiol Biomarkers Prev 2003, 12, 1271–1272.
   PubMed Web of Science ®Google Scholar
• Hultdin, J.; Van Guelpen, B.; Bergh, A.; Plasma folate, vitamin B12, and homocysteine and prostate cancer risk: a prospective study. Int J Cancer 2005, 113, 819–824.
   PubMed Web of Science ®Google Scholar
• Johansson, M.; Appleby, P.N.; Allen, N.E.; Circulating concentrations of folate and vitamin B12 in relation to prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition study. Cancer Epidemiol Biomarkers Prev 2008, 17, 279–285.
   PubMed Web of Science ®Google Scholar
• Vlajinac, H.D.; Marinkovic, J.M.; Ilic, M.D.; Diet and prostate cancer: a case-control study. Eur J Cancer 1997, 33, 101–107.
   PubMed Web of Science ®Google Scholar
• Stevens, V.L.; Rodriguez, C.; Pavluck, A.L.; Folate nutrition and prostate cancer incidence in a large cohort of US men. Am J Epidemiol 2006, 163, 989–996.
   PubMed Web of Science ®Google Scholar
• Lawson, K.A.; Wright, M.E.; Subar, A.; Multivitamin use and risk of prostate cancer in the National Institutes of Health AARP Diet and Health Study. J Natl Cancer Inst 2007, 99, 754–764.
   PubMed Web of Science ®Google Scholar
• Weinstein, S.J.; Stolzenberg-Solomon, R.; Pietinen, P.; Dietary factors of one-carbon metabolism and prostate cancer risk. Am J Clin Nutr 2006, 84, 929–935.
   PubMed Web of Science ®Google Scholar
• Pelucchi, C.; Galeone, C.; Talamini, R.; Dietary folate and risk of prostate cancer in Italy. Cancer Epidemiol Biomarkers Prev 2005, 14(4), 944–948.
   PubMed Web of Science ®Google Scholar
• Shahinian, V.B.; Kuo, Y.F.; Freeman, J.L.; Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate cancer. Cancer 2005, 103, 1615–1624.
   PubMed Web of Science ®Google Scholar
• Akaza, H.; Usami, M.; Hinotsu, S.; Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance. Jpn J Clin Oncol 2004, 34, 329–336.
   PubMed Web of Science ®Google Scholar
• Fonseca, R.; Rajkumar, S.V.; White, W.L.; Anemia after orchiectomy. Am J Hematol 1998, 59, 230–233.
   PubMed Web of Science ®Google Scholar
• Strum, S.B.; McDermed, J.E.; Scholz, M.C.; Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 1997, 79(6), 933–941.
   PubMedGoogle Scholar
• Decensi, A.; Torrisi, R.; Fontana, V. Stimulation of erythropoiesis by the non-steroidal anti-androgen nilutamide in men with prostate cancer: evidence for an agonistic effect?. Br J Cancer 1994, 69(3), 617–619.
   PubMed Web of Science ®Google Scholar
• Ornstein, D.K.; Beiser, J.A.; Andriole, G.L. Anaemia in men receiving combined finasteride and flutamide therapy for advanced prostate cancer. BJU Int 1999, 83(1), 43–46.
   PubMed Web of Science ®Google Scholar
• Kobayashi, M.; Nukui, A.; Morita, T. Pure red cell aplasia in a prostate cancer patient treated with leuprolide acetate and chlormadinone acetate. Int J Urol 2005, 12, 1010–1011.
   PubMed Web of Science ®Google Scholar
• Voegeli, T.A.; Kurtz, A.; Grimm, M.O.; Anemia under androgen deprivation: influence of flutamide, cyproterone acetate and orchiectomy on the erythropoietin system. Horm Metab Res 2005, 37, 3789–3793.
   Google Scholar
• Weber, J.P.; Walsh, P.C.; Peters, C.A.; Effect of reversible androgen deprivation on hemoglobin and serum immunoreactive erythropoietin in men. Am J Hematol 1991, 36(3), 190–194.
   PubMed Web of Science ®Google Scholar
• Foresta, C.; Mioni, R.; Bordon, P.; Erythropoietin and testicular steroidogenesis: the role of second messengers. Eur J Endocrinol 1995, 132(1), 103–108.
   PubMed Web of Science ®Google Scholar
• Molinari, P.F. Erythropoietic mechanism of androgens: a critical review and clinical implications. Haematologica 1982, 67(3), 442–460.
   PubMedGoogle Scholar
• Weiss, G. Pathogenesis and treatment of anemia of chronic disease. Blood Rev 2002, 16, 87–96.
   PubMed Web of Science ®Google Scholar
• Kuvibidila, S.; Gauthier, T.; Warrier, R.P.; Increased levels of serum transferrin receptor and serum transferrin receptor/log ferritin ratios in men with prostate cancer and the implications for body-iron stores. J Lab Clin Med 2004, 144, 176–182.
   PubMedGoogle Scholar
• Kuvibidila, S.; Gauthier, T.; Rayford, W. Serum ferritin and transferrin saturation in men with prostate cancer. J Natl Med Assoc 2004, 96, 641–649.
   PubMed Web of Science ®Google Scholar
• Ornstein, D.L.; Zacharski, L.R. Iron stimulates urokinase plasminogen activator expression and activates NF-kappa B in human prostate cancer cells. Nutr Cancer 2007, 58, 115–126.
   PubMed Web of Science ®Google Scholar
• Donat, S.M.; Powell, C.T.; Israeli, R.S.; Reversal by transferrin of growth-inhibitory effect of suramin on hormone-refractory human prostate cancer cells. J Natl Cancer Inst 1995, 87, 41–46.
   PubMed Web of Science ®Google Scholar
• Sternberg, C.N.; Petrylak, D.; Witjes, F.; Satraplatin demonstrates significant clinical benefits for the treatment of patients with HRPC: results of a randomized phase III trial. J Clin Oncol 2007, 25 (18 Suppl.): 5019.
   PubMedGoogle Scholar
• Arcasoy, M.O.; Amin, K.; Vollmer, R.T.; Erythropoietin and erythropoietin receptor expression in human prostate cancer. Mod Pathol 2005, 18, 421–430.
   PubMed Web of Science ®Google Scholar
• Liu, T.; Allaf, M.E.; Lagoda, G.; Erythropoietin receptor expression in the human urogenital tract: immunolocalization in the prostate, neurovascular bundle and penis. BJU Int 2007, 100, 1103–1106.
   PubMed Web of Science ®Google Scholar
• Berdel, W.E.; Oberberg, D.; Reufi, B.; Studies on the role of recombinant human erythropoietin in the growth regulation of human nonhematopoietic tumor cells in vitro. Ann Hematol 1991, 63, 5–8.
   PubMed Web of Science ®Google Scholar
• Harrison, L.; Shasha, D.; Shiaova, L.; Prevalence of anemia in cancer patients undergoing radiation therapy. Semin Oncol 2001, 28(2 Suppl. 8), 54–59.
   PubMed Web of Science ®Google Scholar
• Bashir, F.A.; Parry, J.M.; Windsor, P.M. Use of modified hemi-body irradiation technique for metastatic carcinoma of the prostate: report of a 10-years experience. Clin Oncol 2008, 20(8), 591–598.
   Web of Science ®Google Scholar
• Biers, S.M.; Sullivan, M.E.; Roberts, I.S.D.; Thrombotic microangiopathy in advanced prostatic carcinoma. Urology 2004, 63, 380iv–380vi.
   Google Scholar
• Mungall S, Mathieson P. Hemolytic uremic syndrome in metastatic adenocarcinoma of the prostate. Am J Kidney Dis 2002, 40(6), 1334–1336.
   PubMed Web of Science ®Google Scholar
• Perkovic, V.; Came, N.A.; Grigg, A.P.; Haemolytic uraemic syndrome and prostatic cancer. Aust N Z J Med 1999, 29, 383–384.
   PubMedGoogle Scholar
• Bern, M.M. Coagulopathy, following medical therapy, for carcinoma of the prostate. Hematology 2005, 10, 65–68.
   PubMed Web of Science ®Google Scholar
• Barker, J. Jr; Wallner, K.; Merrick, G. Gross hematuria after prostate brachytherapy. Urology 2003, 61, 408–411.
   PubMed Web of Science ®Google Scholar
• Lepor, H.; Nieder, A.M.; Ferrandino, M.N. Intraoperative and postoperative complications of radical retropubic prostatectomy in a consecutive series of 1,000 cases. J Urol 2001, 166, 1729–1733.
   PubMed Web of Science ®Google Scholar
• Moul, J.W.; Sun, L.; Wu, H.; Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the Department of Defense (DOD) Center for Prostate Disease Research (CPRD) national database. Urol Oncol 2003, 21, 447–455.
   PubMed Web of Science ®Google Scholar
• Dash, A.; Dunn, R.L.; Resh, J.; Patient, surgeon, and treatment characteristics associated with homologous blood transfusion requirement during radical retropubic prostatectomy: multivariate nomogram to assist patient counseling. Urology 2004, 64, 117–122.
   PubMed Web of Science ®Google Scholar
• Artibani, W.; Grosso, G.; Novara, G.; Is laparoscopic radical prostatectomy better than traditional retropubic radical prostatectomy? An analysis of peri-operative morbidity in two contemporary series in Italy. Eur Urol 2003, 44, 401–406.
   PubMed Web of Science ®Google Scholar
• Parsons, J.K.; Bennett, J.L. Outcomes of retropubic, laparoscopic, and robotic-assisted prostatectomy. Urology 2008, 72, 412–416.
   PubMed Web of Science ®Google Scholar
• Cheema, P.; El-Mefty, O.; Jazieh, A.R. Intraoperative hemorrhage associated with the use of extract of Saw Palmetto herb: a case report and review of literature. J Intern Med 2001, 250, 167–169.
   PubMed Web of Science ®Google Scholar
• Beer, T.M.; Tangen, C.M.; Bland, L.B.; The prognostic value of hemoglobin change after initiating androgen-deprivationtherapy for newly diagnosed metastatic prostate cancer: a multivariate analysis of Southwest Oncology Group Study 8894. Cancer 2006, 107, 489–496.
   PubMed Web of Science ®Google Scholar
• Eisenberger, M.A.; Crawford, E.D.; Wolf, M.; Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036. Semin Oncol 1994, 21, 613–619.
   PubMed Web of Science ®Google Scholar
• Pai, H.H.; Ludgate, C.; Pickles, T.; Hemoglobin levels do not predict biochemical outcome for localized prostate cancer treated with neoadjuvant androgen-suppression therapy and external-beam radiotherapy. Int J Radiat Oncol Biol Phys 2006, 65, 990–998.
   PubMed Web of Science ®Google Scholar
• Shamdas, G.J.; Ahmann, F.R.; Matzner, M.B.; Leukoerythroblastic anemia in metastatic prostate cancer. Clinical and prognostic significance in patients with hormone-refractory disease. Cancer 1993, 71(11), 3594–3600.
   PubMed Web of Science ®Google Scholar
• Ravasco, P.; Monteiro-Grillo I.; Camilo, M.E. Does nutrition influence quality of life in cancer patients undergoing radiotherapy?. Radiother Oncol 2003, 67, 213–220.
   PubMed Web of Science ®Google Scholar
• Aslinia, F.; Mazza, J.J.; Yale, S.H. Megaloblastic anemia and other causes of macrocytosis. Clin Med Res 2006, 4(3), 236–241.
   PubMedGoogle Scholar
• Beer, T.M.; Bergenstock, M.; Birt, K.; Darbepoetin alfa administered every 4 weeks for anemia in patients with advanced prostate cancer. Clin Genitourin Cancer 2007, 5(5), 329–333.
   PubMed Web of Science ®Google Scholar
• Queipo-Zaragoz`, J.A.; Chicote Pérez, F.; Beltr`n Meseguer, J.F.; Improvement of anemia and quality of life of patients with prostate cancer by treatment with human recombinant erythropoietin. Arch Esp Urol 2004, 57(1), 35–40.
   PubMedGoogle Scholar
• Boccon-Gibod, L.; Hammerer, P.; Madersbacher, S.; The role of intermittent androgen deprivation in prostate cancer. BJU Int 2007, 100, 738–743.
   PubMed Web of Science ®Google Scholar
• Wright, J.L.; Higano, C.S.; Lin, D.W. Intermittent androgen deprivation: clinical experience and practical applications. Urol Clin North Am 2006, 33, 167–179.
   PubMed Web of Science ®Google Scholar
• Malone, S.; Perry, G.; Segal, R.; Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study. BJU Int 2005, 96, 514–520.
   PubMed Web of Science ®Google Scholar
• Ferreira, U.; Leitao, V.A.; Denardi, F.; Intermittent androgen replacement for intense hypogonadism symptoms in castrated patients. Prostate Cancer Prostatic Dis 2006, 9, 39–41.
   PubMed Web of Science ®Google Scholar
• Feltquate, D.; Nordquist, L.; Eicher, C.; Rapid androgen cycling as treatment for patients with prostate cancer. Clin Cancer Res 2006, 12, 7414–7421.
   PubMed Web of Science ®Google Scholar
• Johansson, J.E.; Wersall, P.; Brandberg, Y.; Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer -- a randomized study. Scand J Urol Nephrol 2001, 35(4), 288–294.
   PubMed Web of Science ®Google Scholar
• Bogdanos, J.; Karamanolakis, D.; Milathianakis, C.; Epoetin beta (NeoRecormon) corrects anaemia in patients with hormone-refractory prostate cancer and bone metastases. Anticancer Res 2004, 24(3b), 1957–1961.
   PubMed Web of Science ®Google Scholar
• Winquist, E.; Julian, J.A.; Moore, M.J.; Randomized, double-blind, placebo-controlled trial of epoetin alfa in men with castration-resistant prostate cancer and anemia. J Clin Oncol 2009, 26, 644–646.
   Google Scholar
• Ots, P.M.; Pérez, A.R.; Carrizosa, C.L.; Once-weekly dose of epoetin alfa in cancer patients with anemia receiving radiotherapy. Clin Transl Oncol 2005, 7(11), 486–492.
   PubMedGoogle Scholar
• Anast, J.W.; Andriole, G.L.; Grubb, R.L. 2nd. Managing the local complications of locally advanced prostate cancer. Curr Urol Rep 2007, 8, 211–216.
   PubMedGoogle Scholar
• Nabi, G.; Sheikh, N.; Greene, D.; Therapeutic transcatheter arterial embolization in the management of intractable hemorrhage from pelvic urological malignancies: preliminary experience and long-term follow-up. BJU Int 2003, 92, 245–247.
   PubMed Web of Science ®Google Scholar
• Lacombe, L.; Fradet, Y. Blood management and radical retropubic prostatectomy: Quebec experience. Can J Urol 1999, 6, 727–731.
   PubMedGoogle Scholar
• Stoffel, J.T.; Topjian, L.; Libertino, J.A. Analysis of peripheral blood for prostate cells after autologous transfusion given during radical prostatectomy. BJU Int 2005, 96, 313–315.
   PubMed Web of Science ®Google Scholar
• Gaston, K.E.; Kouba, E.; Moore, D.T.; The use of erythropoietin in patients undergoing radical prostatectomy: effects on hematocrit, transfusion rates and quality of life. Urol Int 2006, 77(3), 211–215.
   PubMed Web of Science ®Google Scholar
• Balducci, L.; Ershler, W.B.; Krantz, S. Anemia in the elderly -- Clinical findings and impact on health. Crit Rev Onc Hem 2006, 58, 156–165.
   PubMed Web of Science ®Google Scholar
• Bennett, C.L.; Silver, S.M.; Djulbegovic, B.; Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008, 299(8), 914–924.
   PubMed Web of Science ®Google Scholar
• Geiser, F.; Hahn, C.; Conrad, R.; Interaction of psychological factors and the effect of epoetin-alfa treatment in cancer patients on haemoglobin and fatigue. Support Care Cancer 2007, 15(3), 273–278.
   PubMed Web of Science ®Google Scholar
• Gomella, L.G. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues. BJU Int 2007, 99(Suppl. 1), 25–29.
   PubMedGoogle Scholar
• Carelle, N.; Piotto, E.; Bellanger, A.; Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 2002, 95(1), 155–163.
   PubMed Web of Science ®Google Scholar
• Price, E.A. Aging and erythropoiesis: current state of knowledge. Blood Cells Mol Dis 2008, 41, 158–165.
   PubMed Web of Science ®Google Scholar
• Katz, O.; Gil, L.; Lifshitz, L.; Erythropoietin enhances immune responses in mice. Eur J Immunol 2007, 37(6), 1584–1593.
   PubMed Web of Science ®Google Scholar
• Ferrucci, L.; Maggio, M.; Bandinelli, S.; Low testosterone levels and the risk of anemia in older men and women. Arch Intern Med 2006, 166, 1380–1388.
   PubMed Web of Science ®Google Scholar
• Massa, E.; Madeddu, C.; Lusso, M.R.; Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy. Crit Rev Oncol Hematol 2006, 57(2), 175–182.
   PubMed Web of Science ®Google Scholar
• Kanzaki, M.; Soda, K.; Gin, P.T.; Erythropoietin attenuates cachectic events and decreases production of interleukin-6, a cachexia-inducing cytokine. Cytokine 2005, 32(5), 234–239.
   PubMed Web of Science ®Google Scholar
• Repetto, L.; Fratino, L.; Audisio, R.A.; Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an italian group for geriatric oncology study. J Clin Oncol 2002, 20, 494–502.
   PubMed Web of Science ®Google Scholar
• Manalo, D.J.; Rowan, A.; Lavoie, T.; Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 2005, 105(2), 659–669.
   PubMed Web of Science ®Google Scholar
• Cheng, L.; Zhang, S.; Sweeney, C.J.; Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model. Anticancer Res 2004, 24, 2135–2140.
   PubMed Web of Science ®Google Scholar
• Shasha, D.; Williams, D. Weekly epoetin alfa treatment of anemia in patients with cancer not undergoing therapy. J Support Oncol 2006, 4(3), 129–135.
   PubMedGoogle Scholar
• Maggio, M.; Guralnik, J.M.; Longo, D.L.; Interleukin-6 in aging and chronic disease: a magnificient pathway. J Gerontol A Biol Sci Med Sci 2006, 61, 575–584.
   PubMed Web of Science ®Google Scholar
• Spivak, J.L. The anaemia of cancer: death by a thousand cuts. Nat Rev Cancer 2005, 5, 543–555.
   PubMed Web of Science ®Google Scholar
• Artunc, F.; Risler, T. Serum erythropoietin concentrations and responses to anaemia in patients with or without chronic kidney disease. Nephrol Dial Transplant 2007, 22, 2900–2908.
   PubMed Web of Science ®Google Scholar